This article was originally published Oct. 21.
Pacific Biosciences has raised its maximum aggregate offering price for its planned initial public offering from $230 million to $244.4 million, according to an updated prospectus filed with the Securities and Exchange Commission last week.
The company now plans to register 14.375 million shares of common stock, to be sold for between $15 and $17 per share.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
